Lifesci Capital Forecasts Sutro Biopharma Q1 Earnings

Key Points

• Lifesci Capital issued a Strong‑Buy and forecasted Q1 2026 EPS of ($2.78) for Sutro Biopharma.
• The firm published detailed multi‑year EPS estimates showing persistent losses through FY2030, but projects improvement from FY2026 (‑$6.60) to FY2027 (‑$5.45).
• Shares jumped about 7.9% to roughly $38.39 after the note; the company has a consensus price target of $40.78, multiple analyst upgrades and raised targets, and roughly 97% institutional ownership.

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Lifesci Capital issued their Q1 2026 earnings per share estimates for shares of Sutro Biopharma in a report issued on Friday, May 1st. Lifesci Capital analyst C. Zhu forecasts that the company will post earnings of ($2.78) per share for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Sutro Biopharma's current full-year earnings is ($9.17) per share. Lifesci Capital also issued estimates for Sutro Biopharma's Q2 2026 earnings at ($1.52) EPS, Q3 2026 earnings at ($1.34) EPS, Q4 2026 earnings at ($1.34) EPS, FY2026 earnings at ($6.60) EPS, Q1 2027 earnings at ($1.39) EPS, Q2 2027 earnings at ($1.39) EPS, Q3 2027 earnings at ($1.44) EPS, Q4 2027 earnings at ($1.25) EPS, FY2027 earnings at ($5.45) EPS, FY2028 earnings at ($5.47) EPS, FY2029 earnings at ($5.62) EPS and FY2030 earnings at ($6.31) EPS.

STRO has been the topic of several other research reports. Wall Street Zen upgraded Sutro Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, March 28th. Truist Financial upgraded Sutro Biopharma to a "strong-buy" rating in a research report on Wednesday, March 25th. Wells Fargo & Company upgraded Sutro Biopharma from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $8.00 to $27.00 in a research report on Tuesday, March 24th. Citizens Jmp boosted their price target on Sutro Biopharma from $35.00 to $41.00 and gave the company a "market outperform" rating in a research report on Thursday, April 23rd. Finally, Leerink Partners started coverage on Sutro Biopharma in a research note on Tuesday, April 7th. They set an "outperform" rating and a $38.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.78.

Sutro Biopharma Stock Up 7.9%

Shares of STRO stock opened at $38.39 on Tuesday. The stock has a market capitalization of $636.05 million, a PE ratio of -1.47 and a beta of 1.63. Sutro Biopharma has a 52-week low of $6.74 and a 52-week high of $39.10. The stock's 50-day moving average price is $25.73 and its 200 day moving average price is $16.52.

Institutional Investors Weigh In On Sutro Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of STRO. Invesco Ltd. grew its holdings in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company's stock worth $60,000 after acquiring an additional 53,390 shares during the period. AQR Capital Management LLC grew its holdings in shares of Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock worth $859,000 after acquiring an additional 1,206,330 shares during the period. Strs Ohio acquired a new stake in shares of Sutro Biopharma in the 1st quarter worth approximately $99,000. Marshall Wace LLP acquired a new position in Sutro Biopharma during the second quarter worth about $166,000. Finally, Cerity Partners LLC raised its position in Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company's stock worth $75,000 after acquiring an additional 66,372 shares during the last quarter. Institutional investors and hedge funds own 96.99% of the company's stock.

More Sutro Biopharma News

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Lifesci Capital reiterated a "Strong‑Buy" and published multi‑year EPS forecasts; the firm projects a smaller full‑year loss in FY2027 versus FY2026 (FY2026 est. -$6.60 → FY2027 est. -$5.45), a data point investors are treating as constructive for future valuation. Lifesci Capital research note
• Neutral Sentiment: The report provides detailed quarter‑by‑quarter EPS forecasts through FY2030 (Q1–Q4 2026, Q1–Q4 2027, FY2028–2030), which is useful for financial modeling and setting expectations but does not constitute company guidance. Full estimates
• Negative Sentiment: Despite the bullish rating, the forecasts still show persistent, material losses for multiple years (consensus referenced ~ -$9.17 for the current full year and Lifesci’s long‑range EPS remain negative), underscoring execution and commercialization risk that could pressure the stock if clinical or partnership progress stalls. Estimates and consensus

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.